BFIM
TAK icon

Beese Fulmer Investment Management’s Takeda Pharmaceutical TAK Stock Holding History

Beese Fulmer Investment Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-70
Closed -$1K – 500
2020
Q2 		$1K Buy
+70
New +$1.26K ﹤0.01% 591

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Beese Fulmer Investment Management's TAK Position: Q3 2020 in Review

Beese Fulmer Investment Management sold out of Takeda Pharmaceutical (TAK) in Q3 2020, closing a stake of 70 shares — an estimated $1K sold.

Beese Fulmer Investment Management first reported a position in TAK in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 311 funds tracked by Wall St. Rank hold TAK as of Q3 2020.

  • Beese Fulmer Investment Management reported no remaining Takeda Pharmaceutical position as of Q3 2020 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 70 Takeda Pharmaceutical shares in Q3 2020, an estimated $1K.
  • Beese Fulmer Investment Management first reported a position in Takeda Pharmaceutical in Q2 2020 and held it in 1 quarter.
  • Beese Fulmer Investment Management's Takeda Pharmaceutical position peaked at $1K in Q2 2020.
  • 311 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2020.

Based on Beese Fulmer Investment Management's 13F filing for Q3 2020, filed 8 Oct 2020.